Skip to main content
Premium Trial:

Request an Annual Quote

Exact Sciences Nets $17.6M from Public Offering

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences said after the close of the market on Monday that it had raised net proceeds of $17.6 million from its public offering of 4.2 million shares of common stock.

The firm priced the offering at $4.50 per share.

The Madison, Wis.-based molecular diagnostics firm said that it intends to use the funds for "strategic initiatives" that it may "undertake from time to time." In addition, Exact Sciences said that it would use the proceeds for product development initiatives and to further its efforts to obtain US Food and Drug Administration clearance of its stool-based DNA colorectal cancer screening product.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.